Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Mexco Energy Lacks a Differentiating Incentive

By Josh Enomoto, InvestorPlace Contributor

As a speculative gamble, MXC stock might appeal to some contrarians. However, the fundamental argument for Mexco Energy – or any other oil firm for that matter – is flawed and vulnerable to volatility.

Milestone Pharmaceuticals Is Good for Your Heart, Unless You’re an Investor

By Josh Enomoto, InvestorPlace Contributor

Milestone Pharmaceuticals offers a critical solution for those with an acute heart condition. However, it has a mixture of positives and negatives, making MIST stock a wild wager.

Air Travel Has Some Harsh Reality Checks for General Electric

By Josh Enomoto, InvestorPlace Contributor

There’s no denying that GE stock is levered to relevant business. But it’s also fair to point out that without a recovery in air travel, General Electric faces a gloomy future.

Mixed Messaging Leaves Under Armour Stock Floundering

By Josh Enomoto, InvestorPlace Contributor

Under Armour stock is floundering while its rivals are soaring. But this underperformance is no reason to bet heavily on this company.

Luckin’s Lack of Brand Appeal Hurts Its Comeback Story

By Josh Enomoto, InvestorPlace Contributor

Luckin stock might appeal to contrarians due to its rock-bottom prices. But you should never forget that there’s a reason why.

Load More